Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1557880 | 1.00 | CYP2D6 (0.46) | CYP2D6HSD11B1BDKRB1ALDH1A1OPRM1 | |
| SCHEMBL1557878 | 1.00 | CYP2D6 (0.46) | CYP2D6HSD11B1BDKRB1ALDH1A1OPRM1 | |
| SCHEMBL4201312 | 0.83 | OPRM1 (0.46) | CYP2D6HSD11B1ALDH1A1OPRM1NPC1 | |
| SCHEMBL25938081 | 0.83 | HSD11B1 (0.44) | HSD11B1ALDH1A1OPRM1NPC1RAB9A | |
| SCHEMBL16591279 | 0.83 | CYP2D6 (0.49) | CYP2D6HSD11B1BDKRB1ALDH1A1OPRM1 | |
| SCHEMBL17761262 | 0.83 | CYP2D6 (0.49) | CYP2D6HSD11B1BDKRB1ALDH1A1OPRM1 | |
| SCHEMBL17985304 | 0.82 | MAOB (0.41) | CYP2D6HSD11B1ALDH1A1NPC1LMNA | |
| SCHEMBL1557855 | 0.82 | MAOB (0.41) | CYP2D6HSD11B1ALDH1A1NPC1LMNA | |
| SCHEMBL1558648 | 0.82 | MEN1 (0.51) | CYP2D6HSD11B1ALDH1A1OPRM1NPC1 | |
| SCHEMBL1558649 | 0.82 | MEN1 (0.51) | CYP2D6HSD11B1ALDH1A1OPRM1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738642-B2 | Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160237081-A1 | TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237081-A1 | TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS | GRM2, GRIK2, GRIA2 | CYP2D6 1906/4885HSD11B1 3905/4885BDKRB1 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.